Full Text View
Tabular View
No Study Results Posted
Related Studies
OLE Study to Evaluate Safety / Efficacy of ZD4522
This study has been completed.

First Received on April 2, 2008.   Last Updated on March 13, 2009   History of Changes
Sponsor: AstraZeneca
Information provided by: AstraZeneca
ClinicalTrials.gov Identifier: NCT00654303
  Purpose

The purpose of this study is to assess the long term safety of Crestor.


Condition Intervention Phase
Hypercholesterolaemia
 Drug: Rosuvastatin
 Phase III

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: ZD4522 Long Term Extension Trial

Resource links provided by NLM:

Genetics Home Reference related topics: hypercholesterolemia
MedlinePlus related topics: Cholesterol
Drug Information available for: Rosuvastatin calcium Rosuvastatin
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Safety, as determined by adverse events, laboratory data, physical examination and ECG. [ Time Frame: 12 weekly ]

Secondary Outcome Measures:
  • Success in achieving goals for Cholesterol levels [ Time Frame: 12 weekly ]

Estimated Enrollment: 3500
Study Start Date: August 1999
Study Completion Date: February 2005
Arms Assigned Interventions
Experimental: 1
Rosuvastatin
 Drug: Rosuvastatin
Other Name: Crestor

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Completion of previous Crestor study as listed in the protocol.

Exclusion Criteria:

  • Pregnant or breast feeding women, or not using appropriate contraception.
  • Abnormal lab values as listed in the protocol.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00654303

Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Elinor Miller, MD AstraZeneca
  More Information

No publications provided

Responsible Party: Elisabeth Björk, AstraZeneca
ClinicalTrials.gov Identifier: NCT00654303     History of Changes
Other Study ID Numbers: 4522IL/0034, D3560C00034
Study First Received: April 2, 2008
Last Updated: March 13, 2009
Health Authority: United States: Food and Drug Administration;   Australia: Department of Health and Ageing Therapeutic Goods Administration;   Canada: Health Canada;   Germany: Federal Institute for Drugs and Medical Devices;   Denmark: Danish Medicines Agency;   Spain: Spanish Agency of Medicines;   Finland: Finnish Medicines Agency;   France: Afssaps - French Health Products Safety Agency;   Hungary: National Institute of Pharmacy;   Ireland: Ministry of Health;   Israel: Ministry of Health;   Italy: Ministry of Health;   Netherlands: The Central Committee on Research Involving Human Subjects (CCMO);   Norway: Norwegian Medicines Agency;   Poland: Ministry of Health;   Sweden: The National Board of Health and Welfare;   United Kingdom: Medicines and Healthcare Products Regulatory Agency;   South Africa: Medicines Control Council

Keywords provided by AstraZeneca:
Cholesterol
Hypercholesterolaemia
Statins

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
 Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 09, 2012



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services